Last updated: February 16, 2026
Overview of the Drug
NDC 42291-0017 is Trikafta, a combination therapeutic for cystic fibrosis (CF). It contains elexacaftor, tezacaftor, and ivacaftor. Approved by the FDA in October 2019, Trikafta has become a leading treatment for CF patients with the F508del mutation, covering approximately 90% of the affected population. It is marketed by Vertex Pharmaceuticals.
Market Size and Epidemiology
The CF patient population in the United States is estimated at 30,000 to 35,000 individuals. Approximately 90% carry the F508del mutation, representing around 27,000 to 31,500 patients eligible for Trikafta. Worldwide, the total CF population is approximately 100,000, with a significant proportion in the US and Europe.
Competitive Landscape
Trikafta faces competition from other CF drugs, mainly:
- Symdeko (tezacaftor/ivacaftor): Approved since 2018; used mainly in patients with certain mutations.
- Kalydeco (ivacaftor): Approved since 2012, for a subset of mutations.
- Orkambi (lumacaftor/ivacaftor): Approved since 2015; older formulation.
Trikafta's broader efficacy over earlier therapies has expanded its market penetration, but patent expirations and biosimilar/pharmaceutical competition could challenge its dominance in the coming decade.
Pricing History and Current Price
- In the US, the wholesale list price of Trikafta is approximately $311,000 annually per patient (2019 data). This is based on a monthly wholesale acquisition cost (WAC) of around $25,916.
- The Inflation-Adjusted Price: Since launch, price increases have been minimal, with some discounts and co-pay assistance programs reducing the effective cost for patients.
Market Dynamics
-
Pricing Strategies
Vertex maintains high list prices to maximize revenue but faces pressure from payers and government programs. Cost-effectiveness evaluations have been conducted, with ICER reports noting the high cost relative to benefits, yet treatment remains cost-effective given the severe health burden of CF.
-
Reimbursement and Access
Reimbursement negotiations with Medicaid, Medicare, and commercial insurers influence net prices. Patient assistance programs offset some costs, reducing net revenue per patient.
-
Patent and Exclusivity
Vertex holds patents extending until at least 2030. Periodic patent challenges or litigation could alter market exclusivity.
-
Regulatory and Clinical Pipeline
Vertex is developing next-generation therapies, but no immediate pipeline supplements or replaces Trikafta. Biosimilar entry is unlikely before 2030 due to patent protections and high development costs.
Price Projection Analysis (2023-2033)
| Year |
Estimated Average Price |
Market Penetration |
Notes |
| 2023 |
$310,000 |
80% of eligible patients |
Stable pricing, some discounts |
| 2025 |
$312,000 |
85% penetration |
Slight price inflation; increased use due to expanded indications |
| 2028 |
$315,000 |
90% penetration |
Potential for negotiated discounts; patents still active |
| 2030 |
$320,000 |
90% penetration |
No biosimilar competition; patent protections hold |
| 2033 |
$330,000 |
90-95% penetration |
Slight inflation adjusted for healthcare inflation and R&D costs |
Key Drivers of Price Change:
- Inflation adjustments aligned with healthcare inflation (~2-3% annually).
- Payer negotiations and value-based pricing models.
- Patent expiration timelines and biosimilar/alternative therapies entering the market.
- Development of next-generation CF therapies potentially affecting market share and pricing strategies.
Forecast Risks
- Patent challenges or legal disputes threaten exclusivity.
- Policy shifts toward drug price regulation or increased pricing transparency.
- Market saturation and increased competition, including biosimilars.
- Changes in CF treatment guidelines impacting patient eligibility.
Summary
Trikafta remains a high-cost, high-prescription drug with stable pricing supported by patent protection and market dominance. Price increases are projected to match healthcare inflation, with potential declines or stabilization as patent protections near expiration and biosimilars become viable.
Key Takeaways
- NDC 42291-0017 (Trikafta) dominates the CF treatment market, with annual list prices around $310,000.
- Market size in the US stands at roughly 27,000 to 31,500 patients; global patient estimates are around 100,000.
- Price projections forecast a gradual increase up to approximately $330,000 by 2033, assuming patent protections and no major market disruptions.
- Competitive threats primarily arise from biosimilars and evolving therapies, but largely remain speculative until patent expiry around 2030.
- Payer negotiations and value-based arrangements significantly influence net revenue and market access.
FAQs
1. When are patent protections for Trikafta expected to expire?
Vertex’s key patents are protected until at least 2030, barring legal challenges or new patents.
2. How does the pricing of Trikafta compare internationally?
Prices vary, with some markets offering government-negotiated discounts, making US prices among the highest globally.
3. What are the main factors that could alter the price trajectory?
Patent expiry, biosimilar development, policy changes, and new competing therapies could significantly influence future prices.
4. How does Trikafta’s price compare to earlier CF therapies?
It is substantially more expensive, reflecting its broader efficacy and market exclusivity; older therapies generally cost below $150,000 annually.
5. What is the outlook for biosimilars or next-generation treatments?
Biosimilar entry is unlikely before 2030; upcoming treatments may influence Trikafta's market share but are not expected to replace it immediately.
References
[1] FDA Approval Documents for Trikafta (Vertex Pharmaceuticals, 2019)
[2] IQVIA OneKey and MarketReports (2023)
[3] ICER Report on CF Therapies (2022)
[4] MarketWatch and industry price data (2023)
